Kuros and Synthes Inc. announce license and development agreement

20-Mar-2012 - Switzerland

Kuros Biosurgery AG has signed a license and development agreement with Synthes, Inc.. Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields.

Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, said: “We are delighted to have signed this deal related to our synthetic matrix technologies with Synthes.  Partnering our products with leading marketing partners is a key element of Kuros’ strategy and we are looking forward to a productive working relationship with Synthes”.

Michel Orsinger, President and CEO of Synthes, commented on the partnership: "The Kuros partnership is an important addition to Synthes goal of being a total solutions provider for our customers. The partnership will strengthen both Kuros and Synthes commitment to develop patient focused clinical solutions."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances